Swiss Life Asset Management Ltd Purchases 68,565 Shares of Bristol Myers Squibb Company $BMY

Swiss Life Asset Management Ltd lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,142,844 shares of the biopharmaceutical company’s stock after buying an additional 68,565 shares during the quarter. Swiss Life Asset Management Ltd owned about 0.06% of Bristol Myers Squibb worth $51,542,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $35,000. JPL Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at about $36,000. Finally, Total Investment Management Inc. acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $38,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.7%

Shares of NYSE:BMY opened at $59.31 on Thursday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The business’s 50 day simple moving average is $58.53 and its two-hundred day simple moving average is $51.69. The firm has a market cap of $120.79 billion, a P/E ratio of 17.19, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the prior year, the firm earned $1.67 EPS. The company’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on BMY shares. Leerink Partners boosted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Scotiabank reiterated a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. HSBC increased their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.